What it is
Retatrutide is an investigational triple-agonist that activates GIP, GLP-1, and glucagon receptors. Phase 2 trial data showed average weight reductions exceeding those seen with semaglutide or tirzepatide alone, though Phase 3 results and regulatory review are still pending.
Status
Retatrutide is not currently available through ORIVA or any U.S. provider. It has not been approved by the FDA. We are tracking trial results and will update waitlist members as appropriate options emerge.
Important. Joining the waitlist does not start a doctor-patient relationship and does not guarantee future access to retatrutide. Any treatment decision will require provider review at the time the medication is available.
Join the waitlist
Email [email protected] with the subject line "Retatrutide waitlist". We do not share waitlist contact info with third parties.